[Second-line treatment for advanced non-small-cell lung cancers]

Area of Science:

• Oncology
• Pharmacology

Background:

• Platinum-based chemotherapy is standard for non-small cell lung cancer (NSCLC).
• Many NSCLC patients develop resistance or recurrence after initial platinum-based therapy.
• There is a need for effective second-line treatment options.

Purpose of the Study:

• To evaluate new chemotherapy agents for NSCLC refractory to or recurring after platinum-based chemotherapy.
• To compare the efficacy and safety of novel agents against established treatments.
• To identify optimal second-line chemotherapy strategies for NSCLC.

Main Methods:

• Review of recent phase II and phase III clinical trials.
• Analysis of data on chemotherapy agents including docetaxel, gemcitabine, and pemetrexed.
• Inclusion of data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors like gefitinib and erlotinib.

Main Results:

• Docetaxel is the first agent with proven benefit in recurrent/refractory NSCLC after initial chemotherapy.
• Pemetrexed demonstrated clinically equivalent efficacy to docetaxel but with significantly fewer side effects in phase III trials.
• EGFR tyrosine kinase inhibitors show promise as second-line treatments.

Conclusions:

• Pemetrexed should be considered a standard second-line treatment option for NSCLC when available.
• Further phase III trials are needed to evaluate symptom relief, quality of life, toxicity, and survival benefits of new agents.
• Developing novel second-line chemotherapy regimens remains a critical goal in NSCLC treatment.